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This bulletin presents findings regarding the use of cannabis in Ireland from the third drug prevalence survey of households  
in Ireland and Northern Ireland. A representative sample of adults aged between 15 and 64 years was sampled during late 2010 and 
early 2011. The bulletin presents results regarding use of cannabis on lifetime (ever used), last year prevalence (recent use) and last 
month (current use) prevalence rates for Ireland. Prevalence results are also presented for cannabis dependence and cannabis abuse. 
Finally the bulletin examines a range of important issues including age of first use, frequency of use, methods of using cannabis, how 
cannabis is obtained and the profile of those who take it. The survey was carried out according to standards set by the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA).
Key findings
It should be noted that the ordering of the 
key findings below is according to the order 
of appearance in the bulletin and is not 
intended to reflect the order of importance 
of the findings.
Ireland
n Prevalence rates were 25% for 
lifetime use, 6% for last year use and 
3% for last month use.  While there 
were statistical increases in the rates 
for lifetime prevalence since the last 
general population survey (2006/7), 
last year and last month prevalence 
were relatively unchanged.
n Prevalence rates were highest among 
men and younger adults (15-34 years). 
While increases were found in rates for 
men since the last survey in 2006/7, 
there has been relatively little change in 
women’s rates.
n Among recent cannabis users 9% 
were classified as cannabis dependent. 
Dependence was higher among male 
and among young adult recent users. 
Among all adults (15-64 yrs) the share 
classified as cannabis dependent is less 
than 1%.
n Among recent cannabis users 17% met 
criteria for cannabis abuse. Rates of 
cannabis abuse are higher among male 
and young adult recent users. Among 
all adults (15-64 yrs) just over 1% 
meet the criteria for cannabis abuse.
n Among those who reported ever using 
cannabis (lifetime users) the median 
age of first use was 18 years. This is 
unchanged since the last survey.
n The majority of current cannabis users 
report using cannabis on 1-3 days in 
the month prior to the survey (lowest 
frequency) and this response was most 
common among female and older 
adult current users.
n Since the survey in 2006/7 the share 
of current cannabis users engaging in 
lowest frequency use (1-3 days) has 
increased. The share engaging in highest 
frequency use (20 days or more) has 
decreased, particularly among male  
and young adult current users.
n Herb was the main type of cannabis 
used by current users. The share of 
herb users relative to resin users has 
reversed since 2006/7 when resin was 
the most common form reported.
n The majority of recent cannabis users 
said it would be easy for them to 
obtain cannabis in a given 24-hour 
period.
n The majority of lifetime cannabis users 
said they had never used the drug on a 
regular basis. Of those who have, most 
said they had stopped using.
n The three most common reasons 
given for stopping cannabis use were: 
not wanting to take it any more; it no 
longer being a part of respondents’ 
social life and; health concerns.
n With regard to attitudes to cannabis 
use, most respondents
l Agreed with cannabis use being 
permitted for medical reasons
l Disagreed with cannabis use being 
permitted for recreational reasons
l Disapproved of smoking cannabis 
occasionally
l Considered smoking cannabis on  
a regular basis to be risky
n Rates for lifetime cannabis were highest 
among those classified as Group A 
(professionals and managers) and 
lowest among those in Group D (semi-
skilled and un-skilled).
n Cannabis prevalence rates are highest 
among people renting accommodation: 
Lifetime and last year rates were 
highest among those renting from a 
private landlord, while rates for last 
month use were highest among those 
renting from a local authority/housing 
agency.
n The results show that levels of recent 
and current cannabis use increase with 
higher education: Last year and last 
month prevalence rates were highest 
among students; Lifetime rates were 
highest among those who ceased 
education at 20 years and over and 
among those with third level education. 
Rates were lowest among those who 
ceased education at 15 years or under 
and among those with primary level 
education only.
n Lifetime and last year prevalence 
were highest among those who were 
cohabiting, followed by those who were 
single. Last month rates were highest 
among cohabiting and divorced people.
Bulletin 3Drug use in Ireland 
and Northern Ireland
2010/11 Drug Prevalence Survey: 
Cannabis Results
Drug use in Ireland and Northern Ireland: 2010/11 Drug Prevalence Survey:  
Cannabis Results
2 National Advisory Committee on Drugs and Alcohol 2013
Contents
Key Findings 1
Introduction 3
About the Drug Prevalence Survey 3
What is Prevalence? 3
Cannabis dependence and abuse 4
Understanding the Results of this Bulletin 4
Glossary 6
Results 7
Profile of cannabis users 10
References 11
Prevalence Tables
Table 1: Cannabis – Prevalence Rates 12
Table 1a: Cannabis Dependence and Cannabis Abuse using M-CIDI instrument 12
Table 2a-d: Age of First Use and Age of First Regular Use of Cannabis 13
Table 3: Frequency of use of cannabis per month (Current users) 14
Table 4: Type of cannabis commonly used (Current users) 14
Table 5: Cannabis grown in Ireland (Current users who smoke grass/weed/herb/skunk) 14
Table 6: Method of taking cannabis (Current users) 15
Table 7: How cannabis was obtained on last occasion used (Recent users) 15
Table 8: Where cannabis was obtained on last occasion used (Recent users) 15
Table 9: Ease of obtaining cannabis in a 24-hour period (Recent users) 16
Table 10: Regular cannabis users and stopping cannabis use 16
Table 11: Reasons for stopping cannabis use (Ever regular users who stopped using) 16
Table 12: Attitudes towards cannabis use 17
Table 13: Cannabis prevalence by socio-economic group 18
Table 14: Cannabis Prevalence by Work Status 18
Table 15: Cannabis Prevalence by Housing Tenure 18
Table 16: Cannabis Prevalence by Age Education Ceased 19
Table 17: Cannabis Prevalence by Highest Education Level Attained 19
Table 18: Personally Know People who Take Cannabis 19
Table 19: Cannabis Prevalence by Marital Status 19
Drug use in Ireland and Northern Ireland: 2010/11 Drug Prevalence Survey:  
Cannabis Results
3National Advisory Committee on Drugs and Alcohol 2013
Introduction
The survey was commissioned by the National Advisory 
Committee on Drugs (NACD) in Ireland and the Public Health 
Information & Research Branch (PHIRB) within the Department 
of Health, Social Services and Public Safety (DHSSPS) in 
Northern Ireland. This bulletin presents results for Ireland only.
The National Advisory Committee on Drugs (NACD) has been 
reconstituted for the period until the end of 2016, in line with 
the timescale of the National Drugs Strategy. The Committee  
has been extended to incorporate alcohol as well as drugs 
and, to reflect this, it will henceforth be known as the National 
Advisory Committee on Drugs and Alcohol (NACDA).
The role of the new Committee is to advise Government 
on the prevalence, prevention, treatment, rehabilitation and 
consequences of substance use and misuse in Ireland, based on 
the analysis of research findings and information available to it.
About the Drug Prevalence Survey
The questionnaire and methodology for the general population 
survey were based on best practice guidelines drawn up by the 
EMCDDA. The questionnaires were administered through face-
to-face interviews with respondents aged between 15 and 64 
years and who are normally resident in households in Ireland 
and Northern Ireland. Thus persons outside these age ranges, or 
who do not normally live in private households, have not been 
included in the survey (for example prisons, nursing homes etc).
Fieldwork for the survey was carried out between October 2010 
and May 2011 and the final achieved sample comprised 7,669 
respondents (5,134 in Ireland and 2,535 in Northern Ireland). 
Interviews were conducted using computer-assisted personal 
interviewing (CAPI). These techniques allow interviews to be 
conducted more efficiently and more accurately than techniques 
such as pen-and-paper completion.
The response rate for the survey was 60% in Ireland and 67% 
in Northern Ireland. Area based sampling was applied in Ireland. 
The first stage involved stratifying by Health Board in Ireland1. 
The achieved sample was weighted by gender, age and region2 
in Ireland and by gender, age and Health and Social Care Trust 
area in Northern Ireland3 to maximise representativeness of the 
general population.
Details of the methodology have been summarised in a paper 
published on the websites of the NACD (http://www.nacd.ie/) 
and the DHSSPS (http://www.dhsspsni.gov.uk/).
What is Prevalence?
The term prevalence refers to the proportion of a population 
who have used a drug over a particular time period. In general 
population surveys prevalence is measured by asking respondents 
in a representative sample drawn from the population to recall 
their use of drugs. The three most widely used recall periods 
are: lifetime (ever used a drug), last year (used a drug in the 
last twelve months), and last month (used a drug in the last 
30 days). Provided that a sample is representative of the total 
population, prevalence information obtained from a sample 
can be used to infer prevalence in the population.
Lifetime prevalence refers to the proportion of the sample 
that reported ever having used the named drug at the time 
they were surveyed. A person who records lifetime prevalence 
may or may not be currently using the drug. Lifetime prevalence 
should not be interpreted as meaning that people have necessarily 
used a drug over a long period of time or that they will use the 
drug in future. However lifetime information is a core EMCDDA 
requirement, allowing analysis and international comparisons 
of outcomes e.g. continuation/discontinuation rates.
Last year prevalence refers to the proportion of the sample 
that reported using a named drug in the year prior to the 
survey. Last year prevalence is often referred to as recent use.
Last month prevalence refers to the proportion of the sample 
that reported using a named drug in the 30 day period prior  
to the survey. Last month prevalence is often referred to as 
current use. A proportion of those reporting current use may 
be occasional (or first-time) users who happen to have used 
in the period leading up to the survey – it should therefore  
be noted that current use is not synonymous with regular use.
As with other European surveys, people over the age of 64 
are excluded from this survey as they grew up in an era when 
both the use and availability of illegal drugs were very limited. 
Therefore surveys with older people have, to date, shown 
very low rates of use even on a lifetime basis. This situation 
will change over time as the younger population grows older. 
Hence lifetime prevalence rates are likely to increase for a 
considerable period of time. When examining the data and 
comparing results for illicit drugs over time, last year use is  
the best reflection of changes as it refers to recent use.
1 Since January 2005 the Health Boards in Ireland have been restructured and merged under one authority, the Health Service Executive. For the purpose of 
comparisons with earlier surveys it was decided to continue to weight the data by former Health Board areas as these correspond with Regional Drug Task Forces.
2 The composition of the population in Ireland changed substantially since Census 2006. Given that Census 2011 information was not available when weights 
were calculated, data were weighted using 2010 population estimates. For the purpose of constructing post-stratification weights, Regional Authority areas were 
used to define regions instead of Health Board/RDTF.
3 Since the 2006/7 Survey the Health and Social Services Boards and the Health and Social Care Trusts have been restructured. In the 2010/11 survey the data 
have been weighted by the five Health and Social Care Trust areas, while in the previous two surveys the data was weighted by the four Health and Social 
Services Boards that existed at the time.
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Cannabis dependence and abuse
The Diagnostic and Statistical Manual of Psychiatric Disorders 
(DSM), better known as the DSM-IV, is published by the 
American Psychiatric Association and covers all mental health 
disorders for children and adults. The details of cannabis 
dependence and cannabis abuse as defined4 by the DSM-IV  
are outlined below.
DSM-IV substance abuse criteria: Substance abuse is defined 
by the DSM-IV as a maladaptive pattern of substance use leading 
to a clinically significant impairment or distress as manifested by 
one (or more) of the following, occurring with a twelve month 
period:
1. Recurrent substance use resulting in a failure to fulfill major 
role obligations at work, school, or home (such as repeated 
absences or poor work performance related to substance 
use; substance-related absences, suspensions, or expulsions 
from school; or neglect of children or household).
2. Recurrent substance use in situations in which it is physically 
hazardous (such as driving an automobile or operating a 
machine when impaired by substance use)
3. Recurrent substance-related legal problems (such as arrests 
for substance related disorderly conduct)
4. Continued substance use despite having persistent or 
recurrent social or interpersonal problems caused or 
exacerbated by the effects of the substance (for example, 
arguments with spouse about consequences of intoxication 
and physical fights).
DSM-IV substance dependence criteria: DSM-IV also defines 
substance dependence as a maladaptive pattern of substance 
use, leading to clinically significant impairment or distress. But 
substance dependence is manifested by different criteria i.e. 
three (or more) of the following, occurring any time in the same 
12-month period:
1. Tolerance, as defined by either of the following: (a) A need 
for markedly increased amounts of the substance to achieve 
intoxication or the desired effect or (b) Markedly diminished 
effect with continued use of the same amount of the 
substance
2. Withdrawal, as manifested by either of the following: (a) The 
characteristic withdrawal syndrome for the substance or (b) 
The same (or closely related) substance is taken to relieve or 
avoid withdrawal symptoms.
3. The substance is often taken in larger amounts or over a 
longer period than intended.
4. There is a persistent desire or unsuccessful efforts to cut 
down or control substance use.
5. A great deal of time is spent in activities necessary to obtain 
the substance, use the substance, or recover from its effects.
6. Important social, occupational, or recreational activities are 
given up or reduced because of substance use.
7. The substance use is continued despite knowledge of having 
a persistent physical or psychological problem that is likely 
to have been caused or exacerbated by the substance (for 
example, current cocaine use despite recognition of cocaine-
induced depression or continued drinking despite recognition 
that an ulcer was made worse by alcohol consumption).
Munich-Composite International Diagnostic 
Interview (M-CIDI)
The Composite International Diagnostic Interview (CIDI, World 
Health Organization, 1990) is a widely accepted and frequently 
used operationalisation of the DSM-IV diagnostic criteria. 
Advised by the EMCDDA, the abbreviated version, the Munich 
Composite International Diagnostic Interview (M-CIDI), a 19 
item instrument reflecting the four cannabis abuse and seven 
cannabis dependence criteria, was used for the NACD 2010 
Drug Prevalence Survey. Details of the instruments and questions 
used and a discussion of measurement issues regarding general 
population survey in Ireland will be reported separately in 
forthcoming NACDA publications.
Understanding the Results  
of this Bulletin
This bulletin contains prevalence rates and other relevant 
information regarding the use of cannabis in Ireland for 
2010/11. Results are given for all respondents (all adults aged 
15-64 years) and for gender and age (15-34 and 35-64 years) 
categories.
Comparisons between 2010/11 and earlier survey results are 
presented for prevalence, frequency of use, age of first use.
Statistical significance tests for changes over time have been 
undertaken and changes that reach the threshold for statistical 
significance have been included in reporting (for further details 
see below). The figures for 2006/7 and 2002/3 in Ireland 
reported in this bulletin may differ slightly from figures report in 
earlier publications. These differences are due to the application 
of improved estimation procedures for comparing data over time.
4 American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. Washington D.C.: American Psychiatric Association.  
(pp. 181-183)
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All prevalence rates presented in the accompanying tables 
are rounded to one decimal place and are rounded to whole 
numbers in the text. Where it provides for a better understanding 
of the situation, figures are sometimes reported in the text at 
one decimal place (e.g. small/low figures).
Invalid responses have been excluded from all analyses. 
Percentages may not always sum to 100 due to either the effect 
of rounding or that respondents could give more than one 
answer.
Reliability of the Estimates
Effects of survey design and statistical significance: 
The vast majority of surveys employ complex design features 
including stratification and clustering as well as weighting 
adjustments. These features greatly improve the efficiency and 
coverage of the survey but their effects must be taken into 
account in data analysis and estimation. The analyses for the 
2011 NACD bulletins/reports incorporate these effects and are 
addressed in the following ways: (i) The confidence intervals 
for prevalence estimates are design effect adjusted using the 
Clopper Pearson method; (ii) For the change in prevalence over 
time, significance levels are calculated on the basis of design-
effect adjusted Newcombe-Wilson Hybrid Confidence Intervals; 
(iii) Ordinal and non-normally distributed metric outcomes are 
modelled in an ordinal regression framework with Wald F-Test 
as significance test. This is the equivalent of a Mann-Whitney-
Wilcoxon test for complex surveys5; (iv) Similarly, the significance 
of associations between prevalence rates and multi-categorical 
grouping variables is tested by Wald F-Tests for logistic regression 
models.
The tests of statistical significance are used to establish the 
degree of confidence with which we can infer that the observed 
changes in drug prevalence between 2010/11 and 2006/7 are 
not due to sampling error. For the change in prevalence over 
time, a significance level of 5% has been specified which means 
that the likelihood that sampling error accounts for the observed 
change is less than 5%. More stringent criteria are used for the 
tests of association for instance between prevalence and socio-
economic group: for these, significance levels of 1% and 0.1% 
are used. For greater transparency the actual significance level 
p rather than the threshold value is reported when discussing 
results of tests of association.
In statistical testing, a result is deemed statistically significant if 
it is unlikely to have occurred by chance, and hence provides 
enough evidence to reject the hypothesis of ‘no effect’. As used 
in statistics, significant does not mean important or meaningful, 
as it does in everyday speech. It is important to realize that 
statistical significance and substantive or practical significance 
are not the same. A small, but important, real-world difference 
may fail to reach significance in a statistical test. Conversely, a 
statistically significant finding may have no practical consequence. 
This is especially important to remember when working with 
large sample sizes because any difference can be statistically 
significant if the samples are extremely large. Whether the 
change is of practical importance is reflected in an evaluation  
of effect size, which is a substantive issue.
Robustness: Sometimes bivariate association can be 
confounded by other variables most notably gender and age. 
Where this is the case in the reporting of Ireland data, it is noted 
in the text and findings that are not robust are not included in 
the key findings section.
Limitations of the General Population Survey 
Methodology
A general population drug prevalence survey has some 
limitations. Some groups with high drug use prevalence are not 
covered by the general population survey method (for example 
the homeless, those in prison). Additionally, drug prevalence 
questions are considered to be sensitive and therefore people 
may refuse to participate or they may under-report their drug 
use. Moreover, for some groups the numbers can be too small 
for reliable prevalence estimations and for these specific groups, 
general population prevalence estimates can be supplemented 
by other methods (e.g. capture-recapture for problem drug 
use and surveys targeting special populations (e.g. prisoners, 
students, early school leavers)).
In order to assess reliability of the drug prevalence estimates, 
95% confidence intervals have been calculated and are available 
at the NACDA website.
5 Natarajan S, Lipsitz S, Fitzmaurice GM, Sinha D, Ibrahim JG, Haas J, Gellad W, An extension of the Wilcoxon rank sum test for complex sample survey data, 
Journal of the Royal Statistical Society, Applied Statistics (2012), 61/4: 653-644.
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Glossary
Bong
A water pipe through which hot smoke is cooled down before 
inhaling.
Grass/Weed
Slang terms for herbal cannabis.
Hash, Hashish
Cannabis resin.
Hash Oil
A purified and concentrated form of resin or herbal cannabis
Herb
The fresh or (more commonly) dried leaves and flowering  
tops of plant.
Joint
A cannabis cigarette (also known as a spliff, reefer etc.).
Skunk
A type of high-potency herbal cannabis.
Resin
Produced by separating the resinous parts of plant from leaves 
etc.
SOC2000 Classification
In Ireland socio-economic grouping is based on a classification of 
occupation and coded to the Standard Occupation Classification 
2000.
A Professionals, senior management and top civil servants
B Middle management, senior civil servants, managers and 
owners of business
C1 Junior management and owners of small businesses
C2 Skilled manual workers and manual workers responsible 
for other workers
D Semi-skilled and unskilled manual workers, trainees and 
apprentices
E All those dependent on the State long-term
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Results
Prevalence rates and comparisons between 
2006/7 and 2010/11 (Table 1)
Among all adults rates of cannabis prevalence in 2010/11 are 
25% (lifetime), 6% (last year) and 3% (last month). Since 
2006/7 there has been a statistically significant increase in the 
lifetime prevalence of cannabis (+3.4 percentage points) in 
Ireland. There has been no other statistically significant change in 
cannabis prevalence among all adults (15-64 yrs) since 2006/7.
Gender
Prevalence rates for cannabis are higher among men for lifetime 
(33% vs 18%), last year (9% vs 3%) and last month (5% vs 
1%) measures. The differences between men and women’s 
2010/11 prevalence rates are statistically significant.
Since 2006/7 lifetime rates for men increased (+6 percentage 
points) while for women rates changed very little (less than one 
percentage point). There was no other statistically significant 
change in cannabis prevalence among men or women since 
2006/7.
Age
Cannabis prevalence rates are substantially higher among young 
(15-34 yrs) than older (35-64 yrs) adults and this is the case 
for lifetime (33% vs 19%), last year (10% vs 3%) and last 
month (5% vs 1%) prevalence. The differences in 2010/11 
between young and older adults’ prevalence rates are statistically 
significant.
Since 2006/7 lifetime prevalence rates among young adults 
increased (+4.8 percentage points). There were no statistically 
significant changes in cannabis prevalence rates among older 
adults.
Cannabis Dependence and Cannabis Abuse 
(Table 1a)
In relation to substance related disorders the DSM-IV manual 
identifies: substance abuse and substance dependence. 
Prevalence results for both of these disorders are presented 
below – first rates for recent cannabis users and this is followed 
by rates for the general population.
Recent cannabis users: Of recent cannabis users, 9% fulfil 
criteria for cannabis dependence; the share is higher among 
male recent users (11%) than female recent users (4%) and 
higher among young adult (15-34) recent users (10%) than 
older (35-64) recent users (7%).
With regard to cannabis abuse (Table 1a) 17% of recent users 
were classified as fulfilling criteria for cannabis abuse. Results by 
gender show that among recent users 20% of men and 8% of 
women abuse cannabis and 20% of young adults and 9% of 
older adults do so.
General population: Among all adults (15-64 yrs) surveyed 
less than 1% have been classified as cannabis dependent. The 
likelihood of cannabis dependence is higher among men (1%) 
than women (0.1%) and higher among young adults (1%) 
compared to older adults (0.3%).
Just over 1% of the general population meet criteria for cannabis 
abuse which when broken down by gender cannabis abuse is 
more prevalent among men (2%) than women (0.3%) and 
more prevalence among young adults (3%) than older adults 
(0.3%).
Age of First Use and Age of First Regular Use 
(Table 2)
Age of first use (ever used) (Table 2a): The median age at 
which respondents first used cannabis was 18 years: A median 
age of 18 years was found for men and women alike as well 
as for young adults. For older adults the median age of first use 
was 20 years. Among lifetime cannabis users there has been no 
change in the median age of first cannabis use since the survey 
in 2006/7.
Age of first use (ever regularly used) (Table 2b): Among 
those who ever regularly used cannabis the median age of first 
use is 17 years and this was the case for both men and women. 
The median age of first use is 16 years for young adults (15-34 
yrs) and is slightly higher for older adults at 18 years.
Age of first regular use among those who had ever used 
regularly (Table 2c): Table 2a also presents results for age of 
first regular use of cannabis. Among respondents who said that 
they had used cannabis regularly at some point in their lives, the 
median age of first regular use was 18 years. This is higher for 
women than men (19 vs 18 years) and higher for older than 
young adults (19 vs 18 years).
Number of years between first use and first regular use 
(Table 2d): The period of time between first using cannabis and 
becoming a regular user was two years for all adults. This time 
lag applied to all sub-groups examined except for older adults 
(35-64 yrs), for whom the time lag was three years (Table 2d).
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Frequency of Use (current users6) (Table 3)
Table 3 shows results of frequency of use in the month prior to 
the survey for current cannabis users. Of this group the most 
common response (48%) was 1-3 days in the month prior to 
the survey (i.e. lowest frequency use category). The next most 
frequent response was given by 21% of current cannabis users 
who reported using on 4-9 days in the month before the survey.
Highest frequency use i.e. on 20 or more days was reported by 
14% of current cannabis users. Highest frequency use was more 
likely reported by men (14%) than women (12%) and more 
likely by older (24%) than young (10%) adults.
The proportion of all adults reporting lowest frequency use has 
increased (+10.8 percentage points) since 2006/7 and this was 
found for men (+12.7 percentage points) and women (+5.6 
percentage points). For the highest frequency use category 
the proportion of adults reporting this category declined (-10.5 
percentage points) since 2006/7. The decline was larger among 
men (-13.4 percentage points) than women (-0.8 percentage 
points). Changes in frequency of use between 2006/7 and 
2010/11 are not statically significant6.
Since 2006/7 the share of young adults reporting highest 
frequency use more than halved (-15 percentage points) while 
low frequency use increased (+8 percentage points). Among 
older adults increases were found for high frequency use (+1.6 
percentage points) and low frequency use (+17.7 percentage 
points). These age-related differences are not statistically 
significant6.
Type of cannabis most commonly used  
(Table 4)7
The results presented in Table 4 show current cannabis users 
reported use of ‘weed’ (47%), ‘grass’ (22%) and skunk (2%). 
Together this means that herb (71%) is the most common 
form of cannabis used by current users in 2010/11. Resin was 
reported by more than one quarter (27%) of current users and 
types mentioned were ‘hash’ (23%) and ‘resin’ (4%). Among 
current users herb is more common among men (71%) than 
women (67%) and among young adults (76%) than older 
adults (58%). Resin is more common among men (27%) than 
women (24%) and among older adults (34%) than younger 
adults (24%).
Comparing results over time shows that the share of herb 
relative to resin users has reversed since 2006/7 when resin 
was the most common form used by current users. The 
largest decreases were in found in forms of resin (hash (-31.2 
percentage points), resin (-2.2 percentage points). A decrease 
was also found in use of grass (-5 percentage points). Since the 
2006/7 the largest increases have been in forms of cannabis 
herb: weed (+38.1 percentage points) and skunk (+1.2 
percentage points). Statistically significant changes over time 
were found for men (p=.0000) and young adults (p=.0000)  
but not for women or older adults6.
Smokers of herbal cannabis and whether 
substance is grown in Ireland (Table 5)
Respondents who reported current cannabis use and smoked 
herbal cannabis (in the form of grass, weed, herb or skunk) 
were asked whether the cannabis they smoked in the last month 
was grown in Ireland. Of this group the majority (45%) did not 
know whether the cannabis they took was grown in Ireland or 
not, 38% said it was grown in Ireland (up from 16% in 2006/7) 
and 17% said it was not grown in Ireland (down from 51% in 
2006/7).
Method by which cannabis is used (Table 6)
Current cannabis users were asked about the most common 
method used to take cannabis. The most common method 
reported was a joint (94%) while 4% said they used a pipe. 
Results by gender show that smoking joints was the only method 
reported by women (100%). Smoking joints was also the most 
common method reported by men (93%), followed by a pipe 
(4%) and a bong (2%). Less than 1% of men reported eating 
cannabis. In terms of age, smoking joints was reported more 
by young adults (97%) than older adults (87%) while using a 
pipe was more likely to be reported by older than young adults 
(11% vs 0.6%). Using a bong was reported by 2% of young 
adults and 1% of older adults said they were most likely to eat 
cannabis.
6 The number of current cannabis users in the 2006/7 and 2010/11 surveys is unlikely to be sufficient to detect differences where they occur in the population 
as statistically significant.
7 It should be noted in relation to Table 4 and the discussion of this table, that many of these terms are names for the same form of cannabis (e.g. hash and  
resin are the same form while grass, weed, herb and skunk are terms used for the form known as cannabis herb).
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How cannabis was obtained on last occasion 
used (Table 7)
Recent cannabis users were asked how they got their cannabis 
and most mentioned people that were well known to them: the 
majority mentioned getting cannabis from a family member or 
a friend (45%), followed by getting when friends shared it with 
them (22%) and buying it from a friend (19%). In comparison, 
respondents were much less likely to report getting cannabis 
from a contact not known to them personally: for example 6% 
said they had bought the cannabis from a person not known to 
them and 3% said they had been given cannabis by someone 
who was a contact but was not known to them personally.
Where cannabis was obtained on last 
occasion used (Table 8)
Recent cannabis users were asked where they had obtained 
their cannabis on the last occasion they had used it. Most 
respondents indicated that they had gotten cannabis at the 
house of friends (62%), followed by getting it in a street/park 
(14%), a disco/bar/club (8%), the house of a dealer (6%), 
ordered by telephone (4%) with just over 1% of recent user 
reporting getting cannabis whilst in school/college.
Women were more likely than men to obtain their cannabis in 
the house of a friend (74% vs 58%) and were also more likely 
to order cannabis by telephone than men (6% vs 3%). On 
the other hand men were more likely than women to source 
cannabis in a street or park (17% vs 4%), in a disco/club/bar 
(8% vs 6%) and in a house of a dealer (7% vs 5%).
A similar share of young and older adults reported sourcing 
cannabis at a house of a friend (both 62%). Young adults were 
more likely than older adults to report getting cannabis in a 
street/park (15% vs 8%) and to order cannabis by telephone 
(4% vs 2%). Older adults (35-64 yrs) however were more likely 
to source the cannabis they used in a disco/bar/club (9% vs 
7%) and in the house of a dealer (8% vs 6%).
Ease of obtaining cannabis (Table 9)
Recent cannabis users were asked how easy/difficult it would be 
for them to obtain cannabis in a 24-hour period. Most (73%) 
respondents said that would be easy. The size of this majority 
has increased since 2006/7 (when 60% of recent users said 
it would be easy8). Men (73%) were almost as likely to find it 
easy to obtain cannabis as women (74%). Young adults were 
more likely than older adults to say it would be easy (76% vs 
63%).
Stopping cannabis use and reasons for 
stopping (Table 10)
Lifetime cannabis users were asked if they had ever used 
cannabis on regular basis and 27% of this group said they had. 
This response was more common among men (32%) than 
women (18%) and among young (31%) than older (23%) 
adults.
People who had used cannabis regularly at some point were also 
asked about attempts to stop cannabis use. Of this group 74% 
said they had managed to stop and 10% said they had tried but 
had not succeeded.
Among those who had stopped using cannabis the share of 
women (76%) was higher than men (73%). More men than 
women had never tried to stop (17% vs 12%) while women 
were more likely than men to have tried and failed to stop (13% 
vs 10%).
Equal shares (74%) of young and older adults successfully 
stopped using cannabis. A larger share of young than older 
adults were not successful in their attempts at stopping (11% 
vs 9%). Older adults were marginally more likely to have never 
tried to stop using cannabis than young adults (17% vs 15%).
Reasons for stopping cannabis use (Ever 
regular users who stopped cannabis use) 
(Table 11)
‘Not wanting to use any longer’ was the most common reason 
given by respondents for stopping cannabis use and this 
reason was given by 27% of those who had stopped. After this 
‘cannabis no longer a part of social life’ was a reason given by 
18%, and health concerns was mentioned by 17% of those 
who stopped. Among the remaining reasons the most frequently 
reported were ‘impact on job/friends/family’ and ‘not enjoying 
the after effects’ (both 7%). After this the most frequently 
mentioned responses were being persuaded by friend/family 
members to stop (6%), no longer being able to afford to use 
cannabis (3%), having given up smoking (also 3%), being on 
rehabilitation programme and reduced availability/supply of 
cannabis (both 2%).
Among the reasons given for stopping cannabis use, the most 
common reasons mentioned by men were: no longer wanting 
to take cannabis any longer (29%), concerns about implications 
for health (18%) and cannabis being no longer a part of their 
social life (16%). The most common reasons for stopping given 
by women were: cannabis was no longer a part of their social 
life (25%), not wanting to take cannabis any more (21%) and 
health concerns (12%).
8 Not reported in this bulletin. Please see Drug Use in Ireland and Northern Ireland 2006/7 Drug Prevalence Survey, Cannabis Results (NACD 2008).
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Among the most common reasons for stopping cannabis use, 
young adults mentioned: no longer wanting to take it (28%), 
health concerns (18%) and cannabis no longer being a part 
of their social life (16%). Older adults were most likely to stop 
because they no longer wanted to take it (26%), cannabis was 
no longer part of their social life (22%) and health concerns 
(14%).
Attitudes towards cannabis use (Table 12)
Respondents (15-64 yrs) were asked whether people 
should be permitted to take cannabis for medical 
reasons: Respondents were asked about the extent to 
which they agreed with cannabis use being permitted for 
medical reasons. Most of those surveyed agreed (66%) with 
the statement (comprising 34% who fully agreed and 32% 
who largely agreed). Men were more likely to agree with this 
statement than women (72% vs 60%) as were older than 
young adults (69%vs 62%).
Table 12 shows separate results for two different sub-
samples: lifetime cannabis users and those who had never 
used cannabis. In both sub-samples the majority agreed with 
the statement and agreement was higher among men and older 
adults. Lifetime cannabis users were more likely to agree with 
the statement than those who had never used (85% vs 60%).
Respondents (15-64 yrs) were asked whether people 
should be permitted to take cannabis for recreational 
reasons: In this case, the majority of respondents disagreed 
(69%) with this statement (comprised of 46% reporting ‘fully 
disagree’ and the 23% reporting ‘largely disagree’). Women 
(78%) were more likely to disagree than men (61%) and older 
(72%) were more likely to disagree than young adults (66%).
Responses were analysed for lifetime users and those 
who had never used cannabis separately: Among those 
who have never used cannabis, a large majority (80%) 
disagreed with the idea that cannabis should be permitted for 
recreational reasons. Among lifetime users more respondents 
agreed (44%) than disagreed (38%) with the statement.
Respondents (15-64 yrs) were asked about extent of 
approval/disapproval with smoking cannabis regularly: 
When asked about their views on people smoking cannabis 
regularly, 36% said they strongly disapproved and 37% 
disapproved. A smaller share of respondents said they did not 
disapprove (26%), while less than 1% said they did not know.
Disapproval was higher among those who had never used 
cannabis than among lifetime users (84% vs 40%). For both of 
these sub-groups women were more likely to disapprove than 
men while levels of disapproval were similar between older 
(41%) and young adults (40%).
Respondents (15-64 yrs) were asked about risk from 
smoking cannabis regularly: Respondents surveyed were 
most likely to rate smoking cannabis regularly as a great risk 
(64%). Women were more likely to rate this as risky than men 
(72% vs 56%) as were older adults (69% vs 58%). People 
who had never used cannabis were more likely to rate it as a 
‘great risk’ (72%) than lifetime users (41%).
Profile of cannabis users
Cannabis Prevalence by Socio-economic 
Group (SOC2000 Classification)9 (Table 13)
Cannabis prevalence analysed by socio-economic group status 
show that lifetime and last year rates are highest among people 
in Group A (Professionals, Senior management and top civil 
servants) at 35% and 10% respectively. However the rate for 
current use, last month prevalence is highest among people 
in Group E (Long-term state dependent) (5%). Lifetime rates 
were lowest for Group D (Semi-skilled and unskilled workers) 
(20%). Last year (21%) and last month rates (4%) are lowest 
for C2 (Skilled manual workers and manual workers responsible 
for other workers). However group differences are statistically 
significant for lifetime prevalence only (p=.0001).
Work Status (Table 14)
Cannabis
Table 14 presents 2010/11 results for prevalence of cannabis 
according to the work status of survey respondents. Lifetime 
prevalence is highest among those classified as being in paid 
work, while last year and last month rates are highest among 
students: 11% (last year) and 4% (last month). There are no 
statistically significant group differences.
Housing tenure (Table 15)
Table 15 presents cannabis prevalence rates according to type 
of housing tenure. Lifetime and last year rates for cannabis 
prevalence are highest in the group classified as ‘Renting from 
a private landlord: For this group rates are 37% (lifetime) and 
12% (last year). Last month cannabis prevalence is highest 
among those classified as ‘Renting from a local authority 
or housing agency at 7%. Group differences are statistically 
significant for all three prevalence measures (p=.0000).
9 Official/international system for classifying socio-economic group.
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Age Ceased Education (Table 16)
Table 16 outlines cannabis prevalence by the age people said 
they had ceased formal education. Lifetime cannabis prevalence 
is highest among those who ceased education at 20 years and 
over (34%). Lifetime cannabis rates are 21% for those who 
ceased education between 16-19 years and 19% for those 
who ceased at 15 years or under. Last year and last month 
prevalence rates are highest for those who ceased education 
at 15 years or under (6% and 4%, respectively). Only group 
differences in lifetime prevalence rates are statistically significant 
(p=.0000).
Highest Education Level Attained  
(Table 17)
Table 17 presents cannabis prevalence rates according to the 
highest level of qualification attained by respondents. Lifetime 
rates are highest for those with third level education at 31% 
and lowest among those with primary level (14%). Last year 
prevalence is marginally higher among those with upper second 
level (7%), while the last month rate for those who attained 
primary, lower second and upper second levels is 3% each. 
Only group differences for lifetime rates are statistically significant 
(p=.0000).
Knowing people who use cannabis  
(Table 18)
Of all adults (15-64) surveyed 46% said in 2010/11 that they 
know someone personally who used cannabis. This response 
was more likely among men (53%) than women (40%) and 
among young adults (62%) than older adults (34%).
Marital Status (Table 19)
Table 19 sets out the results for cannabis prevalence according 
to respondents’ marital status. Lifetime rates are highest 
among those classified as cohabiting (47%), followed by those 
classified as single (31%). Last year rates were also highest 
for these groups (13% and 12%) and last month rates were 
highest among those cohabiting and divorced (each 7%). For 
all three prevalence measures, group differences are statistically 
significant.
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Table 1: Cannabis – Prevalence Rates (%)
All adults  
(15-64)
Males Females Young adults  
(15-34)
Older adults  
(35-64)
02/3 06/7 10/11 02/3 06/07 10/11 02/03 06/7 10/11 02/3 06/7 10/11 02/3 06/7 10/11
Total Weighted N 
(valid responses)
4918 4967 5127 2470 2513 2553 2448 2454 2574 2333 2315 2254 2585 2652 2873
Lifetime Prevalence  
(Ever used)
17.3 21.9 25.3ab 22.2 27.2 33.2abc 12.3 16.8 17.5b 23.8 28.6 33.4ab 11.4 16.2 19.0abd
Last Year Prevalence 
(Recent use)
5.1 6.3 6.0 7.2 8.8 9.1 2.9 3.9 2.9 8.7 10.6 10.3 1.8 2.7 2.6d
Last Month Prevalence 
(Current use)
2.6 2.6 2.8 3.4 4.1 4.7c 1.7 1.2 0.9b 4.3 4.3 4.5 0.9 1.2 1.4d
a Denotes a statistically significant change (p<0.05) between 2006/7 and 2010/11.
b Denotes a statistically significant change (p<0.05) between 2002/3 and 2010/11.
c Denotes a statistically significant difference between men and women in 2010/11.
d Denotes a statistically significant difference between age groups in 2010/11.
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses.
Table 1a: Cannabis Dependence and Cannabis Abuse using M-CIDI instrument (recent cannabis users and general 
population) (%)
All adults  
(15-64)
Male Female Young adults  
(15-34)
Older adults  
(35-64)
Recent Users
Total Weighted N (valid responses) 305 231 74 232 73
Cannabis Dependence 9.2 11.0 3.6 9.8 7.3
Cannabis Abuse 17.4 20.4 8.1 20.1 8.9
General Population
Total Weighted N (valid responses) 5,106 2,544 2,562 2,244 2,862
Cannabis Dependence 0.6 1.2 0.1 1.1 0.3
Total Weighted N (valid responses) 4,134 1,939 2,199 1,732 2,402
Cannabis Abuse 1.3 2.4 0.3 2.7 0.3
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Table 2a: Age of first use (Lifetime users)
All adults  
(15-64)
Males Females Young adults  
(15-34)
Older adults  
(35-64)
02/3 06/7 10/11 02/3 06/07 10/11 02/03 06/7 10/11 02/3 06/7 10/11 02/3 06/7 10/11
Total Weighted N 
(valid responses)
750 1087 1298 487 679 848 264 408 450 492 661 753 258 426 545
Median Age 18 18 18 18 18 18 18 18 18 17 18 18 20 20 20
Table 2b: Age of first use (Ever, regular users)
All adults  
(15-64)
Males Females Young adults  
(15-34)
Older adults  
(35-64)
02/3 06/7 10/11 02/3 06/07 10/11 02/03 06/7 10/11 02/3 06/7 10/11 02/3 06/7 10/11
Total Weighted N 
(valid responses)
176 280 354 183 208 272 42 72 82 138 201 230 39 79 124
Median Age 16 17 17 16 17 17 16 17 17 16 17 16 18 19 18
Table 2c: Age of First Regular Use (Ever regularly users)
All adults  
(15-64)
Males Females Young adults  
(15-34)
Older adults  
(35-64)
02/3 06/7 10/11 02/3 06/07 10/11 02/03 06/7 10/11 02/3 06/7 10/11 02/3 06/7 10/11
Total Weighted N 
(valid responses)
166 280 354 126 208 272 40 72 82 130 201 230 36 79 124
Median Age 18 18 18 18 18 18 17 18 19 17 18 18 19 20 19
Table 2d: Average number of years between first use and first regular use (Ever regular users)
All adults  
(15-64)
Males Females Young adults  
(15-34)
Older adults  
(35-64)
02/3 06/7 10/11 02/3 06/07 10/11 02/03 06/7 10/11 02/3 06/7 10/11 02/3 06/7 10/11
Total Weighted N 
(valid responses)
152 276 354 122 205 272 29 72 82 124 198 230 27 79 124
Average no. years 2 2 2 2 2 2 1 2 2 2 2 2 2 2 3
Median is used as a measure of central tendency to avoid extreme values skewing results.
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses.
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Table 3: Frequency of use of cannabis per month (Current users) (%)
All adults  
(15-64)
Males Females Young adults  
(15-34)
Older adults  
(35-64)
06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11
Total Weighted N (valid responses) 128 142 99 119 28 24 97 102 31 41
20 days or more 24.4 13.9 27.8 14.4 12.3 11.5 25.0 9.9 22.4 24.0
10-19 days 10.3 17.1 9.0 17.0 15.0 17.8 11.1 19.9 7.9 10.0
4-9 days 28.3 21.2 29.4 22.1 24.1 16.6 26.9 25.2 32.6 11.2
1-3 days 37.0 47.8 33.8 46.5 48.6 54.2 37.0 45 37.1 54.8
a Denotes a statistically significant change (p<0.001) between 2006/7 and 2010/11.
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses.
Table 4: Type of cannabis commonly used (Current users) (%)
All adults  
(15-64)
Males† Females Young adults†  
(15-34)
Older adults  
(35-64)
06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11
Total Weighted N (valid responses) 128 143 99 119 28 24 97 102 31 41
Hash 53.8 22.6 50.3 23.5 66.2 18.3 53.4 19.2 55.2 31.2
Grass 26.8 21.8 27.8 19.9 23.5 30.9 27.1 12.6 26.0 44.9
Resin 6.4 4.2 6.7 3.8 5.2 6.0 4.3 4.9 13.1 2.3
Weed 8.4 46.5 10.1 49.0 2.5 33.9 11.1 61.3 0.0 9.3
Herb 1.9 – 2.5 – 0.0 – 2.5 – 0.0 –
Skunk 1.2 2.4 1.6 2.5 0.0 2.1 1.6 1.9 0.0 3.6
Hash Oil 0.8 0.7 1.1 0.5 0.0 2.1 0.0 0.0 3.4 2.6
Don’t Know 0.6 1.7 0.0 0.7 2.6 6.8 0.0 0.0 24. 6.1
† Denotes a statistically significant change in pattern of use (p<0.05) between 2006/7 and 2010/11.
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses.
Some of the different terms used for the same form of cannabis (e.g. one form is grass/weed and another form is resin/hash).
Table 5: Cannabis grown in Ireland (Current users who smoke grass/weed/herb/skunk) (%)
All adults  
(15-64)
Males Females Young adults  
(15-34)
Older adults  
(35-64)
06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11
Total Weighted N (valid responses) 49 101 42 85 7 16 4 78 8 23
Yes 16.1 38.3 17.1 39.1 9.9 33.9 10.8 36.3 43.0 45.1
No 51.2 16.5 53.8 17.0 36.3 13.9 55.4 15.7 29.6 19.6
Don’t Know 32.7 45.2 29.0 43.9 53.8 52.2 33.8 48.0 27.4 35.8
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses.
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Table 6: Method of taking cannabis (Current users) (%)
All adults  
(15-64)
Male Female Young adults  
(15-34)
Older adults  
(35-64)
Total Weighted N (valid responses) 143 119 24 102 41
Joint 94.4 93.3 100 97.3 87.0
Pipe 3.4 4.1 0.0 0.6 10.6
Bong 1.5 1.8 0.0 2.1 0.0
Eat 0.7 0.8 0.0 0.0 1.0
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses.
Table 7: How cannabis was obtained on last occasion used (Recent users) (%)
All adults  
(15-64)
Male Female Young adults  
(15-34)
Older adults  
(35-64)
Total Weighted N (valid responses) 306 232 74 232 73
Given by family/friend 45.2 42.8 52.9 40.4 60.5
Shared amongst friends 21.7 19.5 28.7 26.4 7.0
Bought from a friend 18.9 22.0 9.1 19.1 18.3
Bought from contact not known 
personally
5.9 6.7 3.3 6.9 2.7
Given by stranger 0.8 0.8 0.7 0.3 2.3
Given by contact not known personally 3.0 3.6 1.0 3.0 2.8
Bought from a stranger 1.3 1.5 0.5 1.1 1.9
Other 2.3 1.8 3.9 1.6 4.6
Refused to answer 1.0 1.3 0.0 1.3 0.0
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses.
Table 8: Where cannabis was obtained on last occasion used (Recent users) (%)
All adults  
(15-64)
Male Female Young adults  
(15-34)
Older adults  
(35-64)
Total Weighted N (valid responses) 306 232 74 232 73
House of friends 62.2 58.4 74.0 62.4 61.7
Disco/bar/club 7.5 8.0 6.1 6.9 9.4
Street/park 13.5 16.7 3.5 15.2 8.3
Ordered by telephone 3.5 2.5 6.4 3.8 2.4
House of a dealer 6.1 6.6 4.5 5.5 8.0
Other 3.5 3.6 3.1 2.4 7.0
School/college 1.4 1.8 0.0 1.2 2.0
Office/Workplace 0.5 0.6 0.0 0.6 0.0
Don’t know 1.5 1.3 2.4 1.6 1.2
Refused to Answer 0.3 0.4 0.0 0.4 0.0
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Table 9: Ease of obtaining cannabis in a 24-hour period (Recent users) (%)
All adults  
(15-64)
Male Female Young adults  
(15-34)
Older adults  
(35-64)
Total Weighted N (valid responses) 306 232 74 232 73
Very Easy 42.6 44.3 37.2 41.5 46.0
Fairly Easy 30.5 28.4 36.9 34.8 16.8
Neither easy or difficult 11.8 12.9 8.1 12.3 10.1
Fairly difficult 10.3 10.1 11.1 8.7 15.5
Very difficult 2.3 1.9 3.6 1.3 5.6
Don’t know 2.5 2.3 3.2 1.4 6.0
Table 10: Regular cannabis users and stopping cannabis use (%)
All adults  
(15-64)
Male Female Young adults  
(15-34)
Older adults  
(35-64)
Lifetime cannabis users who ever used cannabis regularly
Total Weighted N (valid responses) 1298 849 450 753 545
Yes 27.3 32.0 18.3 30.5 22.8
Ever regular cannabis users and stopping cannabis use
Total Weighted N (valid responses) 354 272 82 230 124
Regular user – stopped taking 74.0 73.4 75.8 74.0 74.0
Regular user – tried to stop but failed 10.4 9.7 12.8 11.4 8.7
Regular users – Never tried to stop 15.6 16.9 11.5 14.6 17.4
Table 11: Reasons for stopping cannabis use (Ever regular users who stopped using) (%)
All adults  
(15-64)
Male Female Young adults  
(15-34)
Older adults  
(35-64)
Total Weighted N (valid responses) 262 200 62 170 92
Did not want to take any more 27.4 29.3 21.4 28.0 26.3
No longer part of social life 18.3 16.2 25.3 16.1 22.4
Did not enjoy after effects 7.2 7.6 6.0 6.5 8.7
Health concerns 16.8 18.2 12.3 18.4 13.9
Persuaded by friends/family 6.2 6.9 4.0 7.6 3.7
Cost/could no longer afford it 3.2 3.3 3.0 4.5 0.9
Impact on job-friends/family 7.3 6.8 8.8 8.0 5.9
Less available supply 2.2 2.3 1.6 0.0 6.1
Pregnancy 1.4 0.0 6.0 1.6 1.2
Pros did not outweigh cons 1.4 0.3 4.7 1.9 0.5
Rehab Programme 1.5 1.4 1.6 0.3 3.5
Gave up smoking cigarettes 2.8 3.2 1.8 2.6 3.3
Other 3.0 2.8 3.6 2.6 3.6
Don’t know 1.3 1.7 0.0 2.0 0.0
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Table 12: Attitudes towards cannabis use (%)
GENERAL POPULATION THOSE WHO HAVE  
NEVER USED CANNABIS
THOSE WHO  
EVER USED CANNABIS
All 
adults  
(15-64)
Male Female Young 
adults  
(15-34)
Older 
adults  
(35-64)
All 
adults  
(15-64)
Male Female Young 
adults  
(15-34)
Older 
adults  
(35-64)
All 
adults  
(15-64)
Male Female Young 
adults  
(15-34)
Older 
adults  
(35-64)
People should be permitted to take cannabis for medical reasons
Total Weighted N 
(valid responses)
(5128) (2554) (2574) (2254)* (2874)* (3829) (1705) (2125) (1501)* (2328)* (1298) (849) (450) (753) (545)
Fully agree 34.3 39.6 28.9 31.6 36.4 27.9 30.6 25.7 23.2 30.9 53.1 57.7 44.4 48.2 59.9
Largely agree 31.5 32.0 31.0 30.6 32.4 31.6 34.2 29.4 28.8 33.3 31.4 27.5 38.7 33.6 28.4
Neither agree or disagree 9.4 8.7 10.1 10.9 8.1 10.3 9.7 10.8 12.0 9.2 6.6 6.7 6.6 8.9 3.6
Largely disagree 11.2 8.3 14.1 13.7 9.3 13.6 10.7 15.9 18.1 10.7 4.1 3.4 5.5 4.7 3.3
Fully disagree 11.1 9.8 12.4 10.8 11.4 13.6 12.8 14.2 14.1 13.3 3.8 3.7 3.8 4.2 3.2
Don’t know 2.5 1.6 3.4 2.7 2.4 3.1 2.0 3.9 3.8 2.6 1.0 1.0 1.0 0.5 1.7
People should be permitted to take cannabis for recreational reasons
Total Weighted N 
(valid responses)
(5128) (2554) (2564) (2254)* (2874)* (3829) (1705) (2125) (1501)* (2328)* (1087) (679) (408) (661) (426)
Fully agree 6.8 9.8 3.8 7.9 5.9 3.0 4.2 2.1 2.9 3.0 18.0 21.1 12.0 17.7 18.3
Largely agree 12.7 17.6 7.7 13.0 12.4 8.0 11.5 5.2 7.5 8.3 26.3 29.8 19.8 23.9 29.7
Neither agree or disagree 10.5 11.4 9.7 13.0 9.0 8.5 9.3 7.8 9.5 7.8 16.7 15.6 18.8 18.6 14.0
Largely disagree 23.4 22.0 24.7 24.0 22.8 24.4 24.7 24.2 26.0 23.4 20.2 16.7 26.8 20.0 20.4
Fully disagree 45.8 38.5 53.0 41.6 49.0 55.2 49.4 59.8 52.9 56.6 18.1 16.6 20.9 19.0 16.8
Don’t know 0.9 0.8 1.1 1.0 0.9 1.0 1.1 1.0 1.2 0.8 0.8 0.3 1.7 0.8 0.9
People smoking cannabis occasionally
Total Weighted N 
(valid responses)
(5128) (2554) (2574) (2254)* (2874)* (3829) (1705) (2125) (1501)* (2328)* (1298) (849) (450) (753) (545)
Do not disapprove 26.2 32.2 20.2 30.2 23.0 14.8 16.9 13.2 15.1 14.6 59.6 62.9 53.2 60.3 58.5
Disapprove 37.4 35.6 39.1 38.6 36.4 39.6 39.6 39.7 42.2 38.0 30.7 27.6 36.6 31.4 29.7
Strongly disapprove 35.7 31.4 39.9 30.2 39.9 44.6 42.6 46.2 41.3 46.7 9.4 9.0 10.1 8.2 11.0
Don’t know 0.8 0.9 0.8 1.0 0.7 1.0 1.0 1.0 1.4 0.7 0.4 0.6 0.1 0.1 0.8
Perceived risk related to smoking cannabis regularly
Total Weighted N 
(valid responses)
(5128) (2554) (2574) (2254)* (2874)* (3829) (1705) (2125) (1501)* (2328)* (1298) (849) (450) (753) (545)
No risk 0.9 1.3 0.6 1.4 0.6 0.4 0.3 0.4 0.4 0.3 2.6 3.3 1.3 3.3 1.7
Slight risk 7.6 10.7 4.7 9.7 6.0 4.5 6.3 3.1 5.7 3.7 16.8 19.3 12.0 17.6 15.7
Moderate risk 26.9 31.1 22.8 31.2 23.6 22.7 26.6 19.5 27.2 19.8 39.4 40.0 38.2 39.1 39.8
Great risk 64.0 56.4 71.5 57.5 69.1 71.8 66.1 76.3 66.2 75.4 41.0 37.1 48.5 40.0 42.5
Don’t know 0.5 0.5 0.6 0.3 0.7 0.7 0.7 0.7 0.5 0.8 0.1 0.2 0.0 0.0 0.3
* Due to rounding, the weighted ns for the gender or age categories do not always sum to the total weighted n.
All figures are based on weighted data, are rounded to the nearest decimal place and are based on valid responses.
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Table 13: Cannabis prevalence by socio-economic group (SOCO2000 Classification) (%)
Lifetime†  
(Ever Used)
Last Year  
(Recent Use)
Last Month  
(Current Use)
Total Weighted N (valid responses) 5083 5082 5082
A. Professional, senior management, top civil servants 35.1 9.8 3.1
B. Middle management, senior civil servants, managers and owners of own business 30.2 5.4 2.2
C1. Junior management and owners of small business 27.1 5.6 2.4
C2. Skilled manual workers and manual workers responsible for other workers 20.6 3.8 1.8
D. Semi-skilled and unskilled manual workers, trainees and apprentices 20.2 6.9 2.9
E. All those dependent on the State long-term 26.2 8.0 5.2
† Wald-F statistically significance test (p<.0001) for a test of equality among groups.
Due to weighting, categories do not always sum to total weighted n.
All figures are based on weighted data, all figures are rounded to the nearest decimal place and are based on valid responses.
Table 14: Cannabis Prevalence by Work Status (%)
Lifetime  
(Ever Used)
Last Year  
(Recent Use)
Last Month  
(Current Use)
Total Weighted N (valid responses) 5117 5115 5115
In paid work 27.9 4.9 2.3
Not in paid work 22.4 6.2 3.2
Student 20.9 10.4 4.1
Other 66.1 0.0 0.0
Due to weighting, categories do not always sum to total weighted n.
All figures are based on weighted data. All figures are based on valid responses and are rounded to the nearest decimal place.
Table 15: Cannabis Prevalence by Housing Tenure (%)
Lifetime†  
(Ever Used)
Last Year†  
(Recent Use)
Last Month†  
(Current Use)
Total Weighted N (valid responses) 5069 5068 5068
Owned in part or full 22.2 4.3 1.8
Rented from private landlord 37.4 11.5 4.9
Rented from LA/HA 28.8 9.3 6.9
Other 19.0 6.9 3.7
† Wald-F statistically significance test (p<.0001) for a test of equality among groups.
Due to weighting, categories do not always sum to total weighted n.
All figures are based on weighted data. All figures are based on valid responses and are rounded to the nearest decimal place.
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Table 16: Cannabis Prevalence by Age Education Ceased (%)
Lifetime†  
(Ever Used)
Last Year  
(Recent Use)
Last Month  
(Current Use)
Total Weighted N (valid responses) 3893 3891 3891
15 years and under 19.4 6.1 4.3
16-19 years 20.7 4.5 2.5
20 years and over 34.0 5.5 2.3
† Wald-F statistically significance test (p<.0001) for a test of equality among groups.
Due to weighting, categories do not always sum to total weighted n.
All figures are based on weighted data. All figures are based on valid responses and are rounded to the nearest decimal place.
Table 17: Cannabis Prevalence by Highest Education Level Attained (%)
Lifetime†  
(Ever Used)
Last Year  
(Recent Use)
Last Month  
(Current Use)
Total Weighted N (valid responses) 5087 5086 5086
Primary 13.7 3.4 3.0
Lower second level 18.0 5.6 2.7
Upper second level 23.4 7.0 3.3
Third level 31.4 5.8 2.4
† Wald-F statistically significance test (p<.0001) for a test of equality among groups.
Due to weighting, categories do not always sum to total weighted n.
All figures are based on weighted data. All figures are based on valid responses and are rounded to the nearest decimal place.
Table 18: Personally Know People who Take Cannabis (%)
All adults  
(15-64)
Males Females Young adults  
(15-34)
Older Adults  
(16-34)
02/3 06/7 10/11 02/3 06/07 10/11 02/03 06/7 10/11 02/3 06/7 10/11 02/3 06/7 10/11
Total Weighted N 
(valid responses)
4870 4868 5024 2442 2473 2511 2428 2395 2513 2316 2270 2199 2554 2599 2825
Yes 35.2 43.2 46.4 41.2 48.2 52.9 29.2 38.0 39.9 48.7 58.5 62.4 23.0 29.8 34.0
Table 19: Cannabis Prevalence by Marital Status (%)
CANNABIS
Lifetime  
(Ever Used)
Last Year  
(Recent Use)
Last Month  
(Current Use)
Total Weighted N (valid responses) 5122 5120 5120
Single 30.8 11.5 4.8
Married 18.4 1.3 0.7
Co-habiting 46.9 12.6 6.8
Separated 26.5 4.5 2.2
Divorced 25.9 8.6 6.6
Widowed 10.0 3.6 3.6
† Wald-F statistically significance test (p<.0001) for a test of equality among groups.
Due to weighting, categories do not always sum to total weighted n.
All figures are based on weighted data. All figures are based on valid responses and are rounded to the nearest decimal place.
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